Pulmonx Corp (NASDAQ:LUNG), a developer of minimally invasive treatments for severe lung disease, reported its fourth quarter and full-year 2025 financial results, delivering a mixed performance against analyst expectations. The company's results and forward-looking guidance present a narrative of near-term challenges countered by strategic financial maneuvers aimed at ensuring long-term stability.
Earnings and Revenue Versus Estimates
For the critical fourth quarter ending December 31, 2025, Pulmonx's financial metrics presented a split outcome relative to Wall Street forecasts. The company's top-line revenue narrowly surpassed expectations, while its bottom-line loss was less severe than anticipated.
- Revenue: The company reported Q4 revenue of $22.6 million. This figure came in slightly above the analyst consensus estimate of approximately $22.16 million.
- Earnings Per Share (EPS): Pulmonx reported a net loss per share of $0.25. This result was notably better than the estimated loss of $0.40 per share that analysts had projected.
The market's initial reaction, observed in after-hours trading, was positive, with shares rising approximately 4.9%. This suggests investors were encouraged by the earnings beat and the company's cost management, which contributed to a lower-than-expected loss.
Full-Year Results and Strategic Highlights
For the full year 2025, Pulmonx achieved worldwide revenue of $90.5 million, an 8% increase over the prior year. However, the quarterly results revealed a more complex picture, with a 5% year-over-year decline in Q4 revenue to $22.6 million. This dip was primarily driven by an 11% decrease in U.S. revenue, partially offset by an 8% increase in international sales.
Beyond the headline numbers, the earnings release emphasized several strategic actions management is taking to navigate a "period of transition," as termed by CEO Glen French. Key highlights from the report include:
- Cost Restructuring: The company executed a cost restructuring initiative aimed at reducing operating expenses. This was reflected in Q4 operating expenses of $27.4 million, an 11% decrease from the same period in 2024.
- Balance Sheet Strengthening: Pulmonx successfully refinanced its existing debt, securing a new five-year, interest-only credit facility for up to $60 million. This extends the company's debt maturity to 2031 and provides access to additional capital.
- Improved Margins and Losses: The company realized a gross margin of 78% in the fourth quarter, up from 74% a year ago. Both net loss and Adjusted EBITDA loss improved year-over-year for the quarter, pointing to progress on the path toward profitability.
Forward Guidance and Analyst Expectations
Management provided financial guidance for the full year 2026, which offers a direct point of comparison with existing analyst models. The company's outlook appears cautious relative to market expectations.
- 2026 Revenue Guidance: Pulmonx expects revenue in the range of $90 million to $92 million. This forecast sits below the current analyst consensus sales estimate for 2026 of approximately $96.1 million.
- Profitability and Cash Flow: The company anticipates a gross margin of approximately 75% and operating expenses between $113 million and $115 million. It also expects its cash balance to decrease by about $23 million over the year, assuming no additional drawdowns on its new credit facility.
The guidance for essentially flat year-over-year revenue growth, juxtaposed with the significant cost-cutting measures, underscores management's stated focus on "financial discipline" and "aligning investments with growth expectations" to build a sustainable business model. The market will likely watch closely for signs that this operational focus can eventually reaccelerate top-line growth.
Conclusion
Pulmonx's Q4 earnings report delivered a beat on both revenue and EPS estimates, driving a positive after-hours market reaction. The results highlight a company in the midst of a strategic pivot, balancing near-term commercial headwinds—particularly in the U.S.—with aggressive cost management and a strengthened balance sheet. While the full-year 2026 revenue guidance suggests a period of consolidation rather than rapid growth, the improved operational efficiency and extended financial runway provide the company with crucial resources to execute its long-term plan. The key question for investors remains whether this period of disciplined investment will successfully rebuild commercial momentum in the quarters ahead.
For a detailed look at Pulmonx's historical earnings, future estimates, and analyst projections, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
